Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health director Christopher R. Reidy acquired equity through routine compensation-related awards. On July 16, 2026 he received 319 restricted stock units tied to a $0.19 dividend and a $109.88 closing price, and on July 15, 2026 he acquired 21 shares via the Directors Deferred Stock Investment Plan, bringing his direct holdings to 17,777 common shares.
Encompass Health Corp director Edward M. Christie III acquired 248 shares of Encompass Health common stock on July 16, 2026 at a weighted average price of $112.43 per share, plus 11 additional shares on July 15, 2026 from dividend-related awards and director fee deferrals, for a total of 259 shares and direct holdings of 9,345 shares.
Williams Terrance reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Terrance Williams received an automatic grant of 29 restricted stock units (RSUs) on July 15, 2026. The RSUs were credited as a dividend equivalent on existing awards, tied to a $0.19 per share common dividend and a $109.88 closing stock price, increasing his direct holdings to 16,859 shares.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Nancy M. Schlichting received an automatic award of 40 restricted stock units tied to Encompass Health common stock on July 15, 2026. The award represents dividend equivalents on existing RSUs, based on a $0.19 per-share dividend and a $109.88 closing price. Following this award, her directly reported holdings total 22,972 shares.
Encompass Health Corp director Kevin J. O'Connor reported an automatic grant/award acquisition of 19 Encompass Health Common Stock-equivalent RSUs on July 15, 2026, at $0.00 per share. These RSUs were credited under existing restricted stock unit agreements in connection with a $0.19 per-share dividend, when the stock closed at $109.88. Following this award, O'Connor directly holds 11,582 shares.
Encompass Health Corp reported that non-employee director Leslye G. Katz acquired 85 Encompass Health Common Stock-equivalent RSUs at $0.00 per unit under a grant/award transaction. These RSUs were credited as dividend equivalents tied to a $0.19 per share common stock dividend, using a $109.88 closing price on July 15, 2026. Following this award, Katz’s direct holdings total 49,643 shares/units.
Encompass Health Corp director Joan E. Herman reported an automatic acquisition of 85 shares of common stock in the form of restricted stock units (RSUs). These RSUs were credited under outstanding award agreements in connection with the July 15, 2026 common stock dividend of $0.19 per share, when the stock’s closing price was $109.88. Following this dividend-equivalent RSU award, Herman directly holds 49,643 shares of Encompass Health common stock.
Hayes Cain A reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp reports that director Cain A. Hayes received a grant of 4 units of Encompass Health Common Stock on July 15, 2026. According to the award terms, these restricted stock units were credited as dividend equivalents following a $0.19 per-share dividend when the stock closed at $109.88. After this award, Hayes holds a total of 2,096 shares directly, reflecting routine, compensation-related accrual rather than an open-market purchase or sale.
CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Greg D. Carmichael received an automatic award of 29 restricted stock units (RSUs) tied to a common stock dividend paid on July 15, 2026. These RSUs were credited at a dividend of $0.19 per share and a closing price of $109.88, bringing his reported direct Encompass Health equity holdings to 20,349 units.
Encompass Health Corporation issued and sold $500 million of 5.875% Senior Notes due 2034 in a private offering, receiving about $491.2 million in net proceeds. The company plans to use this cash, along with existing cash on hand, to redeem at par $400 million of its 4.500% senior notes due 2028, repay $100 million outstanding under its revolving credit facility, and cover related fees and expenses.
The new notes are senior unsecured obligations, guaranteed on a senior unsecured basis by certain subsidiaries, and pay interest semiannually each June 1 and December 1 until maturity on June 1, 2034. The indenture includes optional redemption features, a change-of-control repurchase right at 101% of principal, and customary covenants and events of default, including cross-default and judgment thresholds of $100 million.